Cargando…
Growing evidence of the safety of JAK inhibitors in patients with rheumatoid arthritis
To facitinib and baricitinib are two of the currently available Janus kinase (JAK) inhibitors for the treatment of patients with RA. Randomized controlled trials have shown that these JAK inhibitors are as efficacious as biological DMARDs. Safety profiles of these JAK inhibitors in randomized contro...
Autor principal: | Harigai, Masayoshi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6390880/ https://www.ncbi.nlm.nih.gov/pubmed/30806708 http://dx.doi.org/10.1093/rheumatology/key287 |
Ejemplares similares
-
Selectivity of Janus Kinase Inhibitors in Rheumatoid Arthritis and Other Immune-Mediated Inflammatory Diseases: Is Expectation the Root of All Headache?
por: Harigai, Masayoshi, et al.
Publicado: (2020) -
JAK Inhibitors in Rheumatoid Arthritis: An Evidence-Based Review on the Emerging Clinical Data
por: Harrington, Robert, et al.
Publicado: (2020) -
The Safety Profile of Upadacitinib in Patients with Rheumatoid Arthritis in Japan
por: Yamaoka, Kunihiro, et al.
Publicado: (2021) -
Clinical efficacy of launched JAK inhibitors in rheumatoid arthritis
por: Taylor, Peter C
Publicado: (2019) -
Efficacy and Safety of JAK Inhibitors for Rheumatoid Arthritis: A Meta-Analysis
por: Wang, Faping, et al.
Publicado: (2022)